News Genmab A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:49 2024-05-08 am EDT			5-day change	1st Jan Change
2,003 ^DKK	-0.45%		+1.91%	-7.05%

May. 03	GENMAB : A good start to 2024; guidance unchanged
May. 03	Genmab Posts Q1 Net Profit Surge; Revenue Jumps	MT

Genmab A/S : has published its Articles of Association	12:29pm	PU
Genmab A/S : Articles of association dated May 07, 2024 – English	11:51am	PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise	May. 07	GL
Transactions in Connection with Share Buy-back Program	May. 06	GL
GENMAB : A good start to 2024; guidance unchanged	May. 03
Genmab Posts Q1 Net Profit Surge; Revenue Jumps	May. 02	MT
Genmab A/S : Investor Presentation - May 2024	May. 02	PU
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance	May. 02	MT
Transcript : Genmab A/S, Q1 2024 Earnings Call, May 02, 2024	May. 02
Genmab A/S : Interim Report for the First Quarter of 2024	May. 02	PU
Genmab A/S : First Quarter 2024 Financial Results Presentation	May. 02	PU
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Genmab Announces Financial Results for the First Quarter of 2024	May. 02	GL
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	Apr. 30	MT
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	Apr. 29	MT
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29	GL
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	Apr. 29	CI
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug	Apr. 29	DJ
Transactions in Connection with Share Buy-back Program Genmab	Apr. 29	GL
Transactions in Connection with Share Buy-back Program Genmab	Apr. 22	GL

No results for this search

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT